• About PURE Bioscience
  • Corporation Overview
  • Investor Relations
    • News
    • Stock Quote
    • SEC Filings
    • SEC Section 16 Filings
    • Board of Directors
    • Leadership Team
    • Code of Ethics
    • Contact Investor Relations
• PURE Technologies
  • Silver dihydrogen citrate
  • Tryglyclboride
  • Contact Scientific Team
  • Partnership Inquiries
• PURE Products
  • SDC-Based Hard Surface Disinfectant
  • SDC as an Additive or Active Ingredient
  • FDA Regulated SDC-Based Product Development
  • TCB-Based Pesticides
  • Distribution Inquiries
• Contact PURE
  • Map

• Corporation Overview
• Investor Relations
• News
• Stock Quote
• SEC Filings
• SEC Section 16 Filings
• Board of Directors
• Leadership Team
• Corporate Governance
• Code of Ethics
• Audit Committee Charter
• Compensation Committee Charter
• Shareholder Communications with Directors Policy
• Contact Investor Relations

Corporate Overview

PURE Bioscience (NASDAQ:PURE) develops and markets technology-based bioscience products that provide non-toxic solutions to numerous global health challenges. PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials and boric acid-based pesticides, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Pure Bioscience, headquartered in El Cajon, California, (San Diego metropolitan area), was incorporated in 1992.

Webcast: Taglich Brothers 5th Annual Small Cap Equity Conference